Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ADPT News 6 December 2025 - 6 February 2026

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

U.S. stocks ended Friday modestly higher, but under the surface December 5, 2025 was a rough day for a cluster of high‑beta tech, Brazilian financials, streaming, and crypto‑linked names. The S&P 500 closed around 6,870 points (+0.19%), the Dow Jones Industrial Average added 0.22%, and the Nasdaq Composite rose 0.43%, even as Bitcoin slipped roughly 3% to just under $89,300. Nasdaq Yet individual stocks saw double‑digit percentage drops, driven by contract disappointments, competitive shocks, capital raises, and political risk abroad. Market Snapshot: Calm Indexes, Violent Stock‑Specific Moves That mix of macro calm and idiosyncratic shocks produced a long tail of big losers. Top Stock Losers in U.S.
6 December 2025
··········

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

7 February 2026
Toyota shares rose 2% to 3,780 yen Friday after the company raised its full-year profit forecast and announced CFO Kenta Kon will replace CEO Koji Sato on April 1. Third-quarter net revenues climbed 6.8% to 38.087 trillion yen, but North America posted a 5.6 billion yen operating loss. Toyota’s U.S. ADRs closed up 2.9%. The tender offer for Toyota Industries shares closes Feb. 12.
Go toTop